Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $155 to $160.
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $155 to $160.